Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1642 1644 1675
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17682314 | FORMULATION OF HIGHLY CONCENTRATED PHARMACOLOGICALLY ACTIVE ANTIBODY | Non-Final OA | Kashiv Biosciences, LLC |
| 19409123 | CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION | Non-Final OA | GENENTECH, INC. |
| 18366061 | TRANSFERRIN RECEPTOR BINDING PROTEINS AND CONJUGATES | Non-Final OA | Eli Lilly and Company |
| 18462320 | METHOD OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIES | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18271511 | COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, AND JOINT AND TENDON DISORDERS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17111671 | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND OX40L | Non-Final OA | Sanofi |
| 17641297 | Treatment of Skin Blistering Diseases Using Antibodies | Non-Final OA | University of Cincinnati |
| 18292586 | ENGINEERED IMMUNE CELL THAT SPECIFICALLY TARGETS MESOTHELIN AND USES THEREOF | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18849006 | ANTIGEN-SPECIFIC THERAPY FOR AUTOIMMUNE DISEASES | Non-Final OA | BODHI BIO LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy